Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-464-952"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-464-952"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-464-9682
lpv:speaker	lp:Marc Tarabella2
lpv:spokenAs	member; S&D (2009-07-16--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2010-07-07--2014-06-30)3 unknown; Parti Socialiste (2009-07-16--2014-06-30)3 substitute; Delegation for relations with the United States (2009-09-16--2014-06-30)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-10-07--2014-06-30)3 member; FEMM (2012-01-19--2014-06-30)3 substitute; IMCO (2012-01-19--2014-06-30)3 member; AGRI (2012-01-19--2014-06-30)3 member; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3
lpv:translated text	"I voted for this text. Because of the many serious problems posed recently by dangerous medicines circulating freely on the market with the authorisation of the European Medicines Agency, it is absolutely essential to introduce, as soon as possible, procedures that are clearer, more transparent and subject to sanctions if they are infringed with regard to the clinical trial data, and the selection and training of the Agency’s scientific staff, including the declarations of interest of its experts and committee members who have been actively involved in the Agency’s activities."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph